FilingsTodayMedpace Holdings
At a glance
Medpace Holdings reported 2025 revenue of $2.53B, up 20% from $2.11B in 2024. Over 4 years since 2021 ($1.14B), that is growth of about 22% a year. Operating margin was 21.1%, up from 17.4% in 2021. 2025 was the highest revenue year in this period.
In the last 12 months 9 insiders reported 0 open-market purchases and 37 sales ($456.4M). 1 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $62M by CEO August J. Troendle on Nov 26, 2025.
Medpace Holdings filed 6 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), officer or director change (2), bylaws or fiscal year change (1) and shareholder vote results (1). The latest officer or director change was reported on Jun 4, 2026.
2 of the 20 investors tracked here held Medpace Holdings at the last quarter end, worth $228.4M combined. It is the largest weight for Renaissance Technologies (0.3% of its portfolio), followed by Bridgewater Associates (0%). Reduced: Renaissance Technologies and Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $181.8M | $245.4M | $282.8M | $404.4M | $451.1M |
| Diluted EPS | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined